Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 3 pivotal study of Radiprodil

Next Previous
X
Search
Trial Profile

A phase 3 pivotal study of Radiprodil

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 12 Dec 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Radiprodil (Primary)
  • Indications Behavioural disorders; Seizures
  • Focus Adverse reactions; Registrational; Therapeutic Use

    • Most Recent Events

    • 09 Dec 2024 According to a GRIN Therapeutics media release, company presented an overview of the proposed design which was based on analysis of positive topline data from the Phase 1b Honeycomb trial for this trial at the American Epilepsy Society (AES) Annual Meeting in Los Angeles, California.
    • 21 Nov 2024 According to a GRIN Therapeutics media release, trial is scheduled to initiate in early 2025.
    • 21 Nov 2024 According to a GRIN Therapeutics media release, design of this study will be presented at the American Epilepsy Society's (AES) Annual Meeting, December 6-10 in Los Angeles, CA.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top